Donna Fitzsimons

The ESC/ESH Guidelines represent the views of the ESC and ESH and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time of their dating. The ESC and ESH are not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the ESC/ESH Guidelines and any other official

TEST 02 - Elsevier's Scopus, the largest abstract and citation database of peer-reviewed literature. Search and access research from the science, technology, medicine, social sciences and arts and humanities fields.

The ESC/EAS Guidelines represent the views of the ESC and EAS, and were produced after careful consideration of the scientific and medical knowledge, and the evidence available at the time of their publication. The ESC and EAS is not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the ESC/EAS Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the ESC/EAS Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic, or therapeutic medical strategies; however, the ESC/EAS Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient's health condition and in consultation with that patient and, where appropriate and/or necessary, the patient's caregiver. Nor do the ESC/EAS Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient's case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional's responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.

C-reactive protein CURE Clopidogrel in Unstable Angina to Prevent Recurrent Events CVD cardiovascular disease DALYs disability-adjusted life years DBP diastolic blood

Coronary artery disease (CAD) is a pathological process characterized by atherosclerotic plaque accumulation in the epicardial arteries,
\nwhether obstructive or non-obstructive. This process can be modified by lifestyle adjustments, pharmacological therapies, and invasive
\ninterventions designed to achieve disease stabilization or regression.
\nThe disease can have long, stable periods but can also become unstable at any time, typically due to an acute atherothrombotic event
\ncaused by plaque rupture or erosion. However, the disease is
\nchronic, most often progressive, and hence serious, even in clinically
\napparently silent periods. The dynamic nature of the CAD process
\nresults in various clinical presentations, which can be conveniently categorized as either acute coronary syndromes (ACS) or chronic
\ncoronary syndromes (CCS). The Guidelines presented here refer to
\nthe management of patients with CCS